Exact Mass: 490.2315044
Exact Mass Matches: 490.2315044
Found 500 metabolites which its exact mass value is equals to given mass value 490.2315044
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glimepiride
C24H34N4O5S (490.22497940000005)
Glimepiride is only found in individuals that have used or taken this drug. It is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin. A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D007004 - Hypoglycemic Agents
Rubraflavone C
Rubraflavone C is found in fruits. Rubraflavone C is a constituent of Morus rubra (red mulberry)
Niludipine
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Bis(2-propoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-3,4-dihydropyridine-3,5-dicarboxylate
PA(2:0/18:2(10E,12Z)+=O(9))
C23H39O9P (490.23315740000004)
PA(2:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:2(10E,12Z)+=O(9)/2:0)
C23H39O9P (490.23315740000004)
PA(18:2(10E,12Z)+=O(9)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/2:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:2(9Z,11E)+=O(13))
C23H39O9P (490.23315740000004)
PA(2:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:2(9Z,11E)+=O(13)/2:0)
C23H39O9P (490.23315740000004)
PA(18:2(9Z,11E)+=O(13)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/2:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:3(10,12,15)-OH(9))
C23H39O9P (490.23315740000004)
PA(2:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:3(10,12,15)-OH(9)/2:0)
C23H39O9P (490.23315740000004)
PA(18:3(10,12,15)-OH(9)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/2:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:3(9,11,15)-OH(13))
C23H39O9P (490.23315740000004)
PA(2:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:3(9,11,15)-OH(13)/2:0)
C23H39O9P (490.23315740000004)
PA(18:3(9,11,15)-OH(13)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/2:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Tanariflavanone B
A trihydroxyflavanone that consists of (2S)-2,3-dihydro-2H,4H-2,5-bichromen-4-one skeleton substituted by hydroxy groups at positions 5, 7 and 8, a methyl group at position 2, a prenyl group at position 6 and a 4-methylpent-3-enyl group at position 2. Isolated from Macaranga tanarius, it exhibits alleopathic effect.
Terrequinone A
A bisindole alkaloid that is quinone bearing a hydroxy substituent at position 2, a 3,3-dimethylallyl group at position 5 and two indol-3-yl groups at positions 3 and 6, one of which is carrying a 1,1-dimethylallyl group at position 2.
dorsilurin E
Moralbanone
Artocommunol CD
Artelasticin
Dorsilurin A
Rubraflavone C
DORSILURIN F
A 7-hydroxyflavonol substituted by additional hydroxy groups at positions 5 and 3 and prenyl groups at positions 6, 8 and 4. Isolated from the roots of Dorstenia psilurus, it exhibits alpha-glucosidase inhibitory activity. D007004 - Hypoglycemic Agents > D065089 - Glycoside Hydrolase Inhibitors D004791 - Enzyme Inhibitors
DORSILURIN K
An extended flavonoid that is flavonol with an additional hydroxy group at position 3, two 2,2-dimethyldihydropyrano rings fused to ring A across positions 5, 6 and 7, 8 respectively and a prenyl group at position 4. Isolated from the roots of Dorstenia psilurus, it exhibits alpha-glucosidase inhibitory activity.
(+)-angelicoidenol 2-O-[6-O-S-3-hydroxy-3-methylglutaryl]-beta-D-glucopyranoside|zingiberoside C methyl ester
C23H38O11 (490.24139979999995)
DORSILURIN J
An extended flavonoid that is 7-hydroxyflavonol with an additional hydroxy group at position 3, a 2,2-dimethyldihydropyrano ring fused to ring A across positions 5 and 6, and prenyl groups at positions 8 and 4. Isolated from the roots of Dorstenia psilurus, it exhibits alpha-glucosidase inhibitory activity.
1-[5,7-dihydroxy-2-methyl-6-(3-methylbut-2-enyl)-2-(4-methylpent-3-enyl)chromen-8-yl]-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
(+)-7,7-bis[(5R,7R,9R,10S)-2-oxocadinan-3,6(11)-dien-12,7-olide]
5,7,2,4-tetrahydroxy-3-geranyl-8-prenylflavone|artocommunol CD
(2S)-5,2,4-trihydroxy-8,5-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone
methyl rel-(1R,4aR,8R)-7-(1-(methoxycarbonyl)vinyl)-5,8-diacetoxy-1,2,3,4a,5,6,7,8,9,10,10a-dodecahydro-1,4a-dimethyl-2-oxophenanthrene-1-carboxylate
3-(3,4-dihydroxyphenyl)-1-[6-(3,7-dimethylocta-2,6-dienyl)-5,7-dihydroxy-2,2-dimethylchromen-8-yl]prop-2-en-1-one
(2S,4S,5S,7S,8E,10S,11R)-7-hydroxy-4,14,15,15-tetramethyl-3,13-dioxotricyclo[9.3.1.1(4,8)]hexadeca-1(14),8-diene-2,5,10-triyl triacetate|2alpha,7beta,10alpha-triacetoxy-5alpha-hydroxy-2(3->20)-abeo-taxa-4(20),11-dien-9,13-dione
juncenolide K|rel-(2R,3aS,4Z,8S,8aS,9S,12aS,13S)-8,9,13-tris(acetyloxy)-3a,6,7,8,8a,9,10,11,12a,13-decahydro-1,5,8a-trimethylspiro[benzo[4,5]cyclodeca[1,2-b]furan-12(2H),2-oxiran]-2-one
8-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one|moralbanone
3beta,15beta,19-triacetoxy-6-oxo-6,7-seco-ent-kaur-16-en-7,20-olide|maoesin F
5,7,3-trihydroxy-4,5-(2,2-dimethylpyran)-8,2-di(3-methyl-2-butenyl)-(2S)-flavanone
An extended flavonoid that consists of (2S)-flavanone substituted by hydroxy groups at positions 5, 7 and 3, prenyl groups at positions 8 and 2 and a gem-dimethyl pyran ring fused across positions 4 and 5. Isolated from Dendrolobium lanceolatum, it exhibits antimalarial activity.
Thr Asp Gln Lys
C19H34N6O9 (490.23871540000005)
Ser Glu Gln Lys
C19H34N6O9 (490.23871540000005)
Lys Gln Ser Glu
C19H34N6O9 (490.23871540000005)
Asp Gln Thr Lys
C19H34N6O9 (490.23871540000005)
Thr Asn Lys Glu
C19H34N6O9 (490.23871540000005)
Thr Lys Asn Glu
C19H34N6O9 (490.23871540000005)
Asn Thr Glu Lys
C19H34N6O9 (490.23871540000005)
3-Geranyl-3-prenyl-5,7,2,4-tetrahydroxyflavone
glimepiride
C24H34N4O5S (490.22497940000005)
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D007004 - Hypoglycemic Agents CONFIDENCE standard compound; INTERNAL_ID 2355 CONFIDENCE standard compound; INTERNAL_ID 8512
C26H34O9_12H-3,5a-Epoxy-5H-furo[3,4-i]oxepino[4,3-a]xanthen-12-one, 1,2,3,6,7,7a,10,14,14a,14b-decahydro-6-hydroxy-5-(hydroxymethyl)-3,13-dimethoxy-5,7a,9,14b-tetramethyl
C26H34O9_(1R,2R,4S,7S,8R,9R,10S,11R,12S,13S,14R,17R,18R,19R)-8-Acetoxy-10,19-dihydroxy-1,9,18-trimethyl-15-oxo-16,20-dioxahexacyclo[15.3.2.0~2,13~.0~4,12~.0~7,11~.0~14,19~]docos-5-ene-5-carboxylic acid
C26H34O9_12H-3,5a-Epoxy-5H-furo[3,4-i]oxepino[4,3-a]xanthen-12-one, 1,2,3,6,7,7a,10,14,14a,14b-decahydro-2,6-dihydroxy-3,13-dimethoxy-5,5,7a,9,14b-pentamethyl
Ala Met Asn Arg
C18H34N8O6S (490.23219040000004)
Ala Met Arg Asn
C18H34N8O6S (490.23219040000004)
Ala Asn Met Arg
C18H34N8O6S (490.23219040000004)
Ala Asn Arg Met
C18H34N8O6S (490.23219040000004)
Ala Arg Met Asn
C18H34N8O6S (490.23219040000004)
Ala Arg Asn Met
C18H34N8O6S (490.23219040000004)
Cys Ile Gln Gln
C19H34N6O7S (490.22095740000003)
Cys Leu Gln Gln
C19H34N6O7S (490.22095740000003)
Cys Asn Arg Val
C18H34N8O6S (490.23219040000004)
Cys Asn Val Arg
C18H34N8O6S (490.23219040000004)
Cys Gln Ile Gln
C19H34N6O7S (490.22095740000003)
Cys Gln Leu Gln
C19H34N6O7S (490.22095740000003)
Cys Gln Gln Ile
C19H34N6O7S (490.22095740000003)
Cys Gln Gln Leu
C19H34N6O7S (490.22095740000003)
Cys Arg Asn Val
C18H34N8O6S (490.23219040000004)
Cys Arg Val Asn
C18H34N8O6S (490.23219040000004)
Cys Val Asn Arg
C18H34N8O6S (490.23219040000004)
Cys Val Arg Asn
C18H34N8O6S (490.23219040000004)
Asp Lys Gln Thr
C19H34N6O9 (490.23871540000005)
Asp Lys Thr Gln
C19H34N6O9 (490.23871540000005)
Asp Gln Lys Thr
C19H34N6O9 (490.23871540000005)
Asp Thr Lys Gln
C19H34N6O9 (490.23871540000005)
Asp Thr Gln Lys
C19H34N6O9 (490.23871540000005)
Glu Glu Ile Thr
Glu Glu Leu Thr
Glu Glu Thr Ile
Glu Glu Thr Leu
Glu Ile Glu Thr
Glu Ile Thr Glu
Glu Lys Asn Thr
C19H34N6O9 (490.23871540000005)
Glu Lys Gln Ser
C19H34N6O9 (490.23871540000005)
Glu Lys Ser Gln
C19H34N6O9 (490.23871540000005)
Glu Lys Thr Asn
C19H34N6O9 (490.23871540000005)
Glu Leu Glu Thr
Glu Leu Thr Glu
Glu Asn Lys Thr
C19H34N6O9 (490.23871540000005)
Glu Asn Thr Lys
C19H34N6O9 (490.23871540000005)
Glu Gln Lys Ser
C19H34N6O9 (490.23871540000005)
Glu Gln Ser Lys
C19H34N6O9 (490.23871540000005)
Glu Ser Lys Gln
C19H34N6O9 (490.23871540000005)
Glu Ser Gln Lys
C19H34N6O9 (490.23871540000005)
Glu Thr Glu Ile
Glu Thr Glu Leu
Glu Thr Ile Glu
Glu Thr Lys Asn
C19H34N6O9 (490.23871540000005)
Glu Thr Leu Glu
Glu Thr Asn Lys
C19H34N6O9 (490.23871540000005)
Phe Met Pro Pro
C24H34N4O5S (490.22497940000005)
Phe Pro Met Pro
C24H34N4O5S (490.22497940000005)
Phe Pro Pro Met
C24H34N4O5S (490.22497940000005)
Gly Met Gln Arg
C18H34N8O6S (490.23219040000004)
Gly Met Arg Gln
C18H34N8O6S (490.23219040000004)
Gly Gln Met Arg
C18H34N8O6S (490.23219040000004)
Gly Gln Arg Met
C18H34N8O6S (490.23219040000004)
Gly Arg Met Gln
C18H34N8O6S (490.23219040000004)
Gly Arg Gln Met
C18H34N8O6S (490.23219040000004)
His His Pro Thr
His His Thr Pro
His Pro His Thr
His Pro Thr His
His Thr His Pro
His Thr Pro His
Ile Cys Gln Gln
C19H34N6O7S (490.22095740000003)
Ile Glu Glu Thr
Ile Glu Thr Glu
Ile Met Met Pro
Ile Met Asn Asn
C19H34N6O7S (490.22095740000003)
Ile Met Pro Met
Ile Asn Met Asn
C19H34N6O7S (490.22095740000003)
Ile Asn Asn Met
C19H34N6O7S (490.22095740000003)
Ile Pro Met Met
Ile Gln Cys Gln
C19H34N6O7S (490.22095740000003)
Ile Gln Gln Cys
C19H34N6O7S (490.22095740000003)
Ile Thr Glu Glu
Lys Asp Gln Thr
C19H34N6O9 (490.23871540000005)
Lys Asp Thr Gln
C19H34N6O9 (490.23871540000005)
Lys Glu Asn Thr
C19H34N6O9 (490.23871540000005)
Lys Glu Gln Ser
C19H34N6O9 (490.23871540000005)
Lys Glu Ser Gln
C19H34N6O9 (490.23871540000005)
Lys Glu Thr Asn
C19H34N6O9 (490.23871540000005)
Lys Asn Glu Thr
C19H34N6O9 (490.23871540000005)
Lys Asn Thr Glu
C19H34N6O9 (490.23871540000005)
Lys Gln Asp Thr
C19H34N6O9 (490.23871540000005)
Lys Gln Glu Ser
C19H34N6O9 (490.23871540000005)
Lys Gln Thr Asp
C19H34N6O9 (490.23871540000005)
Lys Ser Glu Gln
C19H34N6O9 (490.23871540000005)
Lys Ser Gln Glu
C19H34N6O9 (490.23871540000005)
Lys Thr Asp Gln
C19H34N6O9 (490.23871540000005)
Lys Thr Glu Asn
C19H34N6O9 (490.23871540000005)
Lys Thr Asn Glu
C19H34N6O9 (490.23871540000005)
Lys Thr Gln Asp
C19H34N6O9 (490.23871540000005)
Leu Cys Gln Gln
C19H34N6O7S (490.22095740000003)
Leu Glu Glu Thr
Leu Glu Thr Glu
Leu Met Met Pro
Leu Met Asn Asn
C19H34N6O7S (490.22095740000003)
Leu Met Pro Met
Leu Asn Met Asn
C19H34N6O7S (490.22095740000003)
Leu Asn Asn Met
C19H34N6O7S (490.22095740000003)
Leu Pro Met Met
Leu Gln Cys Gln
C19H34N6O7S (490.22095740000003)
Leu Gln Gln Cys
C19H34N6O7S (490.22095740000003)
Leu Thr Glu Glu
Met Ala Asn Arg
C18H34N8O6S (490.23219040000004)
Met Ala Arg Asn
C18H34N8O6S (490.23219040000004)
Met Phe Pro Pro
C24H34N4O5S (490.22497940000005)
Met Gly Gln Arg
C18H34N8O6S (490.23219040000004)
Met Gly Arg Gln
C18H34N8O6S (490.23219040000004)
Met Ile Met Pro
Met Ile Asn Asn
C19H34N6O7S (490.22095740000003)
Met Ile Pro Met
Met Leu Met Pro
Met Leu Asn Asn
C19H34N6O7S (490.22095740000003)
Met Leu Pro Met
Met Met Ile Pro
Met Met Leu Pro
Met Met Pro Ile
Met Met Pro Leu
Met Asn Ala Arg
C18H34N8O6S (490.23219040000004)
Met Asn Ile Asn
C19H34N6O7S (490.22095740000003)
Met Asn Leu Asn
C19H34N6O7S (490.22095740000003)
Met Asn Asn Ile
C19H34N6O7S (490.22095740000003)
Met Asn Asn Leu
C19H34N6O7S (490.22095740000003)
Met Asn Gln Val
C19H34N6O7S (490.22095740000003)
Met Asn Arg Ala
C18H34N8O6S (490.23219040000004)
Met Asn Val Gln
C19H34N6O7S (490.22095740000003)
Met Pro Phe Pro
C24H34N4O5S (490.22497940000005)
Met Pro Ile Met
Met Pro Leu Met
Met Pro Met Ile
Met Pro Met Leu
Met Pro Pro Phe
C24H34N4O5S (490.22497940000005)
Met Gln Gly Arg
C18H34N8O6S (490.23219040000004)
Met Gln Asn Val
C19H34N6O7S (490.22095740000003)
Met Gln Arg Gly
C18H34N8O6S (490.23219040000004)
Met Gln Val Asn
C19H34N6O7S (490.22095740000003)
Met Arg Ala Asn
C18H34N8O6S (490.23219040000004)
Met Arg Gly Gln
C18H34N8O6S (490.23219040000004)
Met Arg Asn Ala
C18H34N8O6S (490.23219040000004)
Met Arg Gln Gly
C18H34N8O6S (490.23219040000004)
Met Val Asn Gln
C19H34N6O7S (490.22095740000003)
Met Val Gln Asn
C19H34N6O7S (490.22095740000003)
Asn Ala Met Arg
C18H34N8O6S (490.23219040000004)
Asn Ala Arg Met
C18H34N8O6S (490.23219040000004)
Asn Cys Arg Val
C18H34N8O6S (490.23219040000004)
Asn Cys Val Arg
C18H34N8O6S (490.23219040000004)
Asn Glu Lys Thr
C19H34N6O9 (490.23871540000005)
Asn Glu Thr Lys
C19H34N6O9 (490.23871540000005)
Asn Ile Met Asn
C19H34N6O7S (490.22095740000003)
Asn Ile Asn Met
C19H34N6O7S (490.22095740000003)
Asn Lys Glu Thr
C19H34N6O9 (490.23871540000005)
Asn Lys Thr Glu
C19H34N6O9 (490.23871540000005)
Asn Leu Met Asn
C19H34N6O7S (490.22095740000003)
Asn Leu Asn Met
C19H34N6O7S (490.22095740000003)
Asn Met Ala Arg
C18H34N8O6S (490.23219040000004)
Asn Met Ile Asn
C19H34N6O7S (490.22095740000003)
Asn Met Leu Asn
C19H34N6O7S (490.22095740000003)
Asn Met Asn Ile
C19H34N6O7S (490.22095740000003)
Asn Met Asn Leu
C19H34N6O7S (490.22095740000003)
Asn Met Gln Val
C19H34N6O7S (490.22095740000003)
Asn Met Arg Ala
C18H34N8O6S (490.23219040000004)
Asn Met Val Gln
C19H34N6O7S (490.22095740000003)
Asn Asn Ile Met
C19H34N6O7S (490.22095740000003)
Asn Asn Leu Met
C19H34N6O7S (490.22095740000003)
Asn Asn Met Ile
C19H34N6O7S (490.22095740000003)
Asn Asn Met Leu
C19H34N6O7S (490.22095740000003)
Asn Gln Met Val
C19H34N6O7S (490.22095740000003)
Asn Gln Val Met
C19H34N6O7S (490.22095740000003)
Asn Arg Ala Met
C18H34N8O6S (490.23219040000004)
Asn Arg Cys Val
C18H34N8O6S (490.23219040000004)
Asn Arg Met Ala
C18H34N8O6S (490.23219040000004)
Asn Arg Val Cys
C18H34N8O6S (490.23219040000004)
Asn Thr Lys Glu
C19H34N6O9 (490.23871540000005)
Asn Val Cys Arg
C18H34N8O6S (490.23219040000004)
Asn Val Met Gln
C19H34N6O7S (490.22095740000003)
Asn Val Gln Met
C19H34N6O7S (490.22095740000003)
Asn Val Arg Cys
C18H34N8O6S (490.23219040000004)
Pro Phe Met Pro
C24H34N4O5S (490.22497940000005)
Pro Phe Pro Met
C24H34N4O5S (490.22497940000005)
Pro His His Thr
Pro His Thr His
Pro Ile Met Met
Pro Leu Met Met
Pro Met Phe Pro
C24H34N4O5S (490.22497940000005)
Pro Met Ile Met
Pro Met Leu Met
Pro Met Met Ile
Pro Met Met Leu
Pro Met Pro Phe
C24H34N4O5S (490.22497940000005)
Pro Pro Phe Met
C24H34N4O5S (490.22497940000005)
Pro Pro Met Phe
C24H34N4O5S (490.22497940000005)
Pro Thr His His
Gln Cys Ile Gln
C19H34N6O7S (490.22095740000003)
Gln Cys Leu Gln
C19H34N6O7S (490.22095740000003)
Gln Cys Gln Ile
C19H34N6O7S (490.22095740000003)
Gln Cys Gln Leu
C19H34N6O7S (490.22095740000003)
Gln Asp Lys Thr
C19H34N6O9 (490.23871540000005)
Gln Asp Thr Lys
C19H34N6O9 (490.23871540000005)
Gln Glu Lys Ser
C19H34N6O9 (490.23871540000005)
Gln Glu Ser Lys
C19H34N6O9 (490.23871540000005)
Gln Gly Met Arg
C18H34N8O6S (490.23219040000004)
Gln Gly Arg Met
C18H34N8O6S (490.23219040000004)
Gln Ile Cys Gln
C19H34N6O7S (490.22095740000003)
Gln Ile Gln Cys
C19H34N6O7S (490.22095740000003)
Gln Lys Asp Thr
C19H34N6O9 (490.23871540000005)
Gln Lys Glu Ser
C19H34N6O9 (490.23871540000005)
Gln Lys Ser Glu
C19H34N6O9 (490.23871540000005)
Gln Lys Thr Asp
C19H34N6O9 (490.23871540000005)
Gln Leu Cys Gln
C19H34N6O7S (490.22095740000003)
Gln Leu Gln Cys
C19H34N6O7S (490.22095740000003)
Gln Met Gly Arg
C18H34N8O6S (490.23219040000004)
Gln Met Asn Val
C19H34N6O7S (490.22095740000003)
Gln Met Arg Gly
C18H34N8O6S (490.23219040000004)
Gln Met Val Asn
C19H34N6O7S (490.22095740000003)
Gln Asn Met Val
C19H34N6O7S (490.22095740000003)
Gln Asn Val Met
C19H34N6O7S (490.22095740000003)
Gln Gln Cys Ile
C19H34N6O7S (490.22095740000003)
Gln Gln Cys Leu
C19H34N6O7S (490.22095740000003)
Gln Gln Ile Cys
C19H34N6O7S (490.22095740000003)
Gln Gln Leu Cys
C19H34N6O7S (490.22095740000003)
Gln Arg Gly Met
C18H34N8O6S (490.23219040000004)
Gln Arg Met Gly
C18H34N8O6S (490.23219040000004)
Gln Ser Glu Lys
C19H34N6O9 (490.23871540000005)
Gln Ser Lys Glu
C19H34N6O9 (490.23871540000005)
Gln Thr Asp Lys
C19H34N6O9 (490.23871540000005)
Gln Thr Lys Asp
C19H34N6O9 (490.23871540000005)
Gln Val Met Asn
C19H34N6O7S (490.22095740000003)
Gln Val Asn Met
C19H34N6O7S (490.22095740000003)
Arg Ala Met Asn
C18H34N8O6S (490.23219040000004)
Arg Ala Asn Met
C18H34N8O6S (490.23219040000004)
Arg Cys Asn Val
C18H34N8O6S (490.23219040000004)
Arg Cys Val Asn
C18H34N8O6S (490.23219040000004)
Arg Gly Met Gln
C18H34N8O6S (490.23219040000004)
Arg Gly Gln Met
C18H34N8O6S (490.23219040000004)
Arg Met Ala Asn
C18H34N8O6S (490.23219040000004)
Arg Met Gly Gln
C18H34N8O6S (490.23219040000004)
Arg Met Asn Ala
C18H34N8O6S (490.23219040000004)
Arg Met Gln Gly
C18H34N8O6S (490.23219040000004)
Arg Asn Ala Met
C18H34N8O6S (490.23219040000004)
Arg Asn Cys Val
C18H34N8O6S (490.23219040000004)
Arg Asn Met Ala
C18H34N8O6S (490.23219040000004)
Arg Asn Val Cys
C18H34N8O6S (490.23219040000004)
Arg Gln Gly Met
C18H34N8O6S (490.23219040000004)
Arg Gln Met Gly
C18H34N8O6S (490.23219040000004)
Arg Val Cys Asn
C18H34N8O6S (490.23219040000004)
Arg Val Asn Cys
C18H34N8O6S (490.23219040000004)
Ser Glu Lys Gln
C19H34N6O9 (490.23871540000005)
Ser Lys Glu Gln
C19H34N6O9 (490.23871540000005)
Ser Lys Gln Glu
C19H34N6O9 (490.23871540000005)
Ser Gln Glu Lys
C19H34N6O9 (490.23871540000005)
Ser Gln Lys Glu
C19H34N6O9 (490.23871540000005)
Thr Asp Lys Gln
C19H34N6O9 (490.23871540000005)
Thr Glu Glu Ile
Thr Glu Glu Leu
Thr Glu Ile Glu
Thr Glu Lys Asn
C19H34N6O9 (490.23871540000005)
Thr Glu Leu Glu
Thr Glu Asn Lys
C19H34N6O9 (490.23871540000005)
Thr His His Pro
Thr His Pro His
Thr Ile Glu Glu
Thr Lys Asp Gln
C19H34N6O9 (490.23871540000005)
Thr Lys Glu Asn
C19H34N6O9 (490.23871540000005)
Thr Lys Gln Asp
C19H34N6O9 (490.23871540000005)
Thr Leu Glu Glu
Thr Asn Glu Lys
C19H34N6O9 (490.23871540000005)
Thr Pro His His
Thr Gln Asp Lys
C19H34N6O9 (490.23871540000005)
Thr Gln Lys Asp
C19H34N6O9 (490.23871540000005)
Val Cys Asn Arg
C18H34N8O6S (490.23219040000004)
Val Cys Arg Asn
C18H34N8O6S (490.23219040000004)
Val Met Asn Gln
C19H34N6O7S (490.22095740000003)
Val Met Gln Asn
C19H34N6O7S (490.22095740000003)
Val Asn Cys Arg
C18H34N8O6S (490.23219040000004)
Val Asn Met Gln
C19H34N6O7S (490.22095740000003)
Val Asn Gln Met
C19H34N6O7S (490.22095740000003)
Val Asn Arg Cys
C18H34N8O6S (490.23219040000004)
Val Gln Met Asn
C19H34N6O7S (490.22095740000003)
Val Gln Asn Met
C19H34N6O7S (490.22095740000003)
Val Arg Cys Asn
C18H34N8O6S (490.23219040000004)
Val Arg Asn Cys
C18H34N8O6S (490.23219040000004)
Austalide F
Crocetin glucosyl ester
2,6-dihydroxy-3,13-dimethoxy-5,5,7a,9,14b-pentamethyl-1,2,3,6,7,7a,10,14,14a,14b-decahydro-5H,12H-3,5a-epoxyfuro[3,4-i]oxepino[4,3-a]xanthen-12-one
3,5,6-tri-O-.benzyl-1,2-O-isopropylidene-alpha-D-glucofuranose
Rhodamine 101 inner salt
butane-1,4-diol,hexanedioic acid,5-isocyanato-5-[(1-isocyanatocyclohexa-2,4-dien-1-yl)methyl]cyclohexa-1,3-diene
Ivabradine metabolite N-Demethyl Ivabradine (hydrochloride)
C26H35ClN2O5 (490.22343700000005)
N-((1S)-2-(Dimethylamino)-1-phenylethyl)-6,6-dimethyl-3-((2-methylthieno(3,2-d)pyrimidin-4-yl)amino)-4,6-dihydropyrrolo(3,4-C)pyrazole-5(1H)-carboxamide
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
2-[5-(carboxymethyl)-4-[1-(furan-3-yl)-5,8a-dimethyl-3-oxo-4,6,7,8-tetrahydro-1H-isochromen-6-yl]-4-(hydroxymethyl)-2,2-dimethyloxolan-3-yl]acetic acid
4-hydroxy-3-(1H-indol-3-yl)-5-(3-methylbut-2-enyl)-6-[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]cyclohexa-3,5-diene-1,2-dione
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
C23H39O9P (490.23315740000004)
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
C23H39O9P (490.23315740000004)
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
C23H39O9P (490.23315740000004)
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
C23H39O9P (490.23315740000004)
rac-(2E)-1-[5,7-dihydroxy-2-methyl-6-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-2H-chromen-8-yl]-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
Mallotophilippen D
A member of the class of chalcones that is chalcone substituted by hydroxy groups at positions 3, 4, 2 and 4, a geranyl group at position 3 and a 6,6-dimethyl-3,6-dihydro-2H-pyran ring fused across positions 5 and 6. Isolated from the fruits of Mallotus philippensis, it exhibits anti-inflammatory and immunoregulatory activities.
[(1S,2S,4S,5R,7E,9S,11E,14R,15R)-5,14-diacetyloxy-4,8,12-trimethyl-16-methylidene-17-oxo-3,18-dioxatricyclo[13.3.0.02,4]octadeca-7,11-dien-9-yl] acetate
[(8R,9R,10S)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9S,10R)-9-[4-(3-methylphenyl)phenyl]-6-(2-methylphenyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
1-(2,5-difluorophenyl)-3-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
C25H32F2N4O4 (490.23914959999996)
[(8R,9S,10R)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
1-(2,5-difluorophenyl)-3-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
C25H32F2N4O4 (490.23914959999996)
(1S,9R,10R,11R)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-11-(morpholine-4-carbonyl)-12-(pyridine-4-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(1S,9R,10R,11R)-5-(cyclohexen-1-yl)-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-12-methylsulfonyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
C24H34N4O5S (490.22497940000005)
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
2-(dimethylamino)-N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide
C24H34N4O5S (490.22497940000005)
1-(2,5-difluorophenyl)-3-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
C25H32F2N4O4 (490.23914959999996)
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
[(8S,9R,10S)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
2-(dimethylamino)-N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide
C24H34N4O5S (490.22497940000005)
2-(dimethylamino)-N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide
C24H34N4O5S (490.22497940000005)
2-(dimethylamino)-N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide
C24H34N4O5S (490.22497940000005)
2-(dimethylamino)-N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide
C24H34N4O5S (490.22497940000005)
2-(dimethylamino)-N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide
C24H34N4O5S (490.22497940000005)
2-(dimethylamino)-N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide
C24H34N4O5S (490.22497940000005)
2-(dimethylamino)-N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide
C24H34N4O5S (490.22497940000005)
1-(2,5-difluorophenyl)-3-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
C25H32F2N4O4 (490.23914959999996)
1-(2,5-difluorophenyl)-3-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
C25H32F2N4O4 (490.23914959999996)
1-(2,5-difluorophenyl)-3-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
C25H32F2N4O4 (490.23914959999996)
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C24H34N4O5S (490.22497940000005)
(1R,9S,10S,11S)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-11-(morpholine-4-carbonyl)-12-(pyridine-4-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(1R,9S,10S,11S)-5-(cyclohexen-1-yl)-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-12-methylsulfonyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
C24H34N4O5S (490.22497940000005)
[(8R,9R,10R)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10R)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10S)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
(1S)-N-cyclopentyl-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
C24H34N4O5S (490.22497940000005)
[(1S,2S,5S,8S,9R,10S,11R,12S,15R)-10,15-diacetyloxy-9-hydroxy-12-methyl-6-methylidene-7-oxo-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-12-yl]methyl acetate
5-(2,3-Dimethoxyphenyl)-1-[2-(dimethylamino)ethyl]-4-(5-methyl-1-phenylpyrazole-4-carbonyl)pyrrolidine-2,3-dione
12-Methyl-16-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-8,15-dioxahexacyclo[14.2.1.114,17.01,13.04,12.05,9]icosa-5(9),6-dien-10-one
beta-D-glucosyl crocetin
Beta-D-glucosyl crocetin is a dicarboxylic acid monoester resulting from the formal condensation of one of the carboxylic acid groups of crocetin with the anomeric hydroxy group of beta-D-glucopyranose. It is a dicarboxylic acid monoester and a beta-D-glucoside. It is functionally related to a crocetin and a beta-D-glucose. It is a conjugate acid of a beta-D-glucosyl crocetin(1-). beta-D-glucosyl crocetin is a natural product found in Gardenia jasminoides and Crocus sativus with data available.
(RS)-mallotophilippen E
A racemate composed of equimolar quantities of R- and S- mallotophilippen E. Isolated from the fruits of Mallotus philippensis, it exhibits anti-inflammatory and immunoregulatory activities.
mallotophilippen E
A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 3, 4, 2 and 4, a prenyl group at position 3 and a 6-methyl-6-(4-methylpent-3-en-1-yl)-3,6-dihydro-2H-pyran ring fused across positions 5 and 6
5,7-dihydroxy-2-[8-hydroxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)chromen-6-yl]-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
13,26-dihydroxy-1,6,6,20,24-pentamethyl-7,22-dioxahexacyclo[13.12.0.0²,¹³.0⁵,¹¹.0¹⁶,²⁵.0¹⁸,²³]heptacosa-9,11,16(25),17,19,23-hexaene-8,21-dione
(2s)-5,7-dihydroxy-2-[(2s)-8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)chromen-5-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
5,7-dihydroxy-2-[8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)chromen-5-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
5,7-dihydroxy-2-[8-hydroxy-2-methyl-2-(4-methylpenta-1,3-dien-1-yl)-3,4-dihydro-1-benzopyran-5-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2r)-5,2',4'-trihydroxy-8,5'-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone
{"Ingredient_id": "HBIN006516","Ingredient_name": "(2r)-5,2',4'-trihydroxy-8,5'-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone","Alias": "NA","Ingredient_formula": "C30H34O6","Ingredient_Smile": "CC(=CCC1=C(C=C(C(=C1)C2CC(=O)C3=C(C4=C(C(=C3O2)CC=C(C)C)OC(C=C4)(C)C)O)O)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21701","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(2s)-5,2',4'-trihydroxy-8,5'-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone
{"Ingredient_id": "HBIN006751","Ingredient_name": "(2s)-5,2',4'-trihydroxy-8,5'-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone","Alias": "NA","Ingredient_formula": "C30H34O6","Ingredient_Smile": "CC(=CCC1=C(C=C(C(=C1)C2CC(=O)C3=C(C4=C(C(=C3O2)CC=C(C)C)OC(C=C4)(C)C)O)O)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21702","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}